Skip to content

Roche to halt HIV drug research

Atazanavir approved for first-line treatment in Europe

Nearly all patients with NNRTI resistance could benefit from etravirine, UK analysis shows

New way of attacking HIV looks promising in early trial

Merck licenses fusion inhibitor to International Partnership for Microbicides

Studies begin to define who will do best on bevirimat

CROI: Choice of nucleoside analogue in co-infection: tenofovir associated with better response to HCV therapy

FDA approves generic atazanavir

Boehringer-Ingelheim begins trial of once-daily extended release nevirapine